he metabolic syndrome is present in approximately 20% of general populations in developed countries and in approximately 80% of people with type 2 diabetes. High triglyceride levels, low high-density cholesterol levels and central obesity are three of the five features of the metabolic syndrome and contribute to the increased risk of cardiovascular disease (CVD) among people with the metabolic syndrome. Lifestyle interventions and treatment with statins reduce risk of CVD but absolute risk of cardiovascular events among high-risk populations remains high. This article reviews the options for treating the atherogenic dyslipidaemia associated with the metabolic syndrome.
Get full access to this article
View all access options for this article.
References
1.
Lee WL, Cheung AM, Cape D., Zinman B.Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care2000 ;23:962-8.
2.
Wild SH, Byrne CDThe global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In Byrne CD , Wild SH (eds). The Metabolic Syndrome. Chichester: Wiley, 2005:1-41.
3.
Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ1998;316:823-8.
4.
Hokanson JE, Austin MAPlasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk1996 ;3:213-19.
5.
Guzder RN, Gatling W., Mehta RL, Mullee MA, Byrne CDPrognostic Value of the framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med2005;22:55462.
6.
Guzder RN, Gatling W., Mullee MA, Byrne CDThe impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia2005. (In press).
7.
Nakanishi N. , Takatorige T., Fukuda H. et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract2004 ;64:59-70.
8.
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res1998;6(suppl 2):51s-209s.
9.
Klein S., Burke LE, Bray GA et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation2004;110:2952-67.
10.
Peeters A., Barendregt JJ, Willekens F., Mackenbach JP, Al Mamun A., Bonneux L.Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med2003;138:24-32.
11.
Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement . Circulation2005.
12.
Franklin BA , Kahn JK, Gordon NF, Bonow ROA cardioprotective `polypill`? Independent and additive benefits of lifestyle modification. Am J Cardiol2004;94:162-6.
13.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.
14.
Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366: 1267-78.
15.
LaRosa JC , Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005; 352:1425-35.
16.
Cannon CP, Braunwald E., McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004 ;350:1495-504.
17.
Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med2002;162:1568-76.
18.
Feher M., Elkeles RSFenofibrate in type 2 diabetes: The FIELD study. Br J Diabetes Vasc Dis2005;5:330-3.
19.
Keech A.Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol2005;4:13.
20.
Dormandy JA , Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet2005;366:1279-89.
21.
Freemantle N.How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?BMJ2005;331:836-8.
22.
Buse JB, Rubin CJ, Frederich R. et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther2005;27:1181-95.
23.
Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib . Arterioscler Thromb Vasc Biol2004;24: 490-7.
24.
Brousseau ME , Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL-cholesterol. N Engl J Med2004; 350:1505-15.
25.
Avorn J.Torcetrapib and atorvastatin - should marketing drive the research agenda?N Engl J Med2005;352:2573-6.
26.
Wong NDCardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment. Br J Diabetes Vasc Dis2005;5:305-14.
27.
Shepherd J. , Betteridge J., Van Gaal L.Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin2005;21:665-82.
28.
National Institute of Clinical Excellence.Management of Type 2 Diabetes - management of blood pressure and blood lipids. 2002. London, NICE.
